MSB 3.16% $1.31 mesoblast limited

Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment, page-239

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 315 Posts.
    lightbulb Created with Sketch. 16
    What? "The results of the trial are blinded, there's no way to know anything until a result comes out," You are obviously the one touting misinformation with your claims of 'modelling'. Of course a result can be determined in a blind trial...that's the whole point!

    They have enrolled 90 ppl and analysed their outcomes at 30 days. If the preported result of 75% day 10 discharge in recepients was replicated this would be demonstrated.
    (you do realise they know that there are two cohorts right?)
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.